BLOC I: DRUG DELIVERY AND DEVELOPMENT ................................................................ 3
UNIT 1: Drug delivery .................................................................................................. 3
UNIT 2: Drug development ........................................................................................ 18
BLOC II: PHARMACODYNAMICS AND -KINETICS........................................................... 23
UNIT 3: Pharmacology and drug disposition .............................................................. 23
UNIT 4: Biotransformation ........................................................................................ 29
UNIT 5: Transporters ................................................................................................. 34
BLOC III: GENETIC THERAPY FOR RETINAL DISEASE ..................................................... 39
UNIT 6: Genetic therapy for inherited retinal diseases ................................................ 39
UNIT 7: Gene augmentation therapy (adding DNA) ..................................................... 42
UNIT 8: Splicing modulation therapy (fixing RNA) ....................................................... 46
UNIT 9: Genome editing therapy (fixing DNA) ............................................................. 52
BLOC IV: THERAPY FOR RENAL TUBULOPATHIES .......................................................... 57
UNIT 10: Renal physiology ........................................................................................ 57
UNIT 11: Current studies and therapy of renal tubulopathies ...................................... 62
UNIT 12: Drug-induced renal pathologies .................................................................. 68
BLOC V: MODERN CANCER THERAPIES ....................................................................... 71
UNIT 13: Basic knowledge RTK and cytokine signalling ............................................... 71
UNIT 14: Targeted cancer therapies ........................................................................... 81
BLOC VI: MODERN PAIN MANAGEMENT ....................................................................... 88
UNIT 15: GPCR-mediated signalling .......................................................................... 88
UNIT 16: Pain management (focus on GPCRs) ........................................................... 97
UNIT 17: Clinical aspects of pain management ........................................................ 104
2
, Molecular Therapy
BLOC I: DRUG DELIVERY AND DEVELOPMENT
UNIT 1: Drug delivery
1. General concepts in drug delivery
Drug delivery aims at achieving a high concentration of a drug molecule at the site of action
(absorption of the drug across a biological membrane). In this way, side effects, as for
example for toxic chemotherapeutics, can be reduced and the activity increased. Drug
delivery frequently is combined with targeting approaches.
- Characteristics of classical drugs:
o Small organic molecules.
o Lipophilic: to cross membranes (stomach, intestine...).
o Distribute freely through the body.
o Act by inhibiting enzymes/ receptors.
- Limitations of classical drugs:
o Chemical diversity limited: due to size and lipophilicity.
o Risk of side effects:
▪ Insufficient specificity: cross reactivity with other targets that are
more than one part of the body.
▪ Inhibition of important metabolic routes in non-target organs
(cancer).
o Poor inhibitors of protein-protein interactions are flat surfaces, so it is not as
easy to attach like deep pockets for binding.
o Oligonucleotides offer a very straight-forward way to inhibit or change
protein expression in a highly specific manner.
2. Drug targeting
Enhance the concentration of a drug at its site of action (target).
- Avoid side effects.
- Use expensive drugs more effectively:
o Less total dose.
o Higher concentration for longer period: protect from degradation and
excretion.
- For an established drug molecule.
Dual challenge
- Remain undetected until the target.
- Find and and hit your target.
3. The main components of a nanomedicine
- Surface modification: prevents rapid clearance.
- Targeting ligand: antibody, HER2 (breast cancer cells), growth factors (EGF-A), …
- Drug.
- Matrix: encapsulates and releases the drug. The ratio drug/matrix should be as hig
as possible.
o Liposome.
3
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper mireiasabater24. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €6,35. Je zit daarna nergens aan vast.